ACE-LY-308 Research Study for People with Mantle Cell Lymphoma (MCL)

We would like to let you know about the ACE-LY-308 research study that is taking place at clinic near you. This study is evaluating an oral investigational medication for people who have been diagnosed with MCL, and have never had treatment.

Why is the ACE-LY-308 study being conducted?
Currently, many people with MCL struggle to decide on a course of treatment. While there are approved treatments available, there remains an unmet need to find new treatment options that can more effectively slow or prevent the progression of the cancer. In this study, doctors want to learn more about the effectiveness of the investigational medication when it is combined with two medications that are approved to treat leukemia and non-Hodgkin’s lymphoma.

The investigational medication has been conditionally approved by the FDA for treatment of adult patients with MCL who have received at least one prior therapy. It has not been approved to treat MCL as first line treatment or any other disease. Doctors want to compare the investigational medication to placebo, which looks like the investigational medication, but contains no active ingredient. In addition, all patients will receive the two approved medications. The results of this study will provide more information about the investigational medication and its effect on MCL.

Who is eligible to participate in the ACE-LY-308 study?
To pre-qualify for this study, you must:
- Be 65 years of age or older
- Have been diagnosed with mantle cell lymphoma
- Have not received previous treatment for your mantle cell lymphoma

All study-related visits, tests, and medications will be provided to participants at no cost. In addition, reimbursement for study-related time and travel may be provided.

How can I participate in the ACE-LY-308 study?
To learn more about this study, or to find out if you may qualify, please go to www.echoclinicaltrial.com.
Please note that this website is intended for a US-only audience. If you are based outside of the US and would like to find out more about the study, please visit https://clinicaltrials.gov/ct2/show/NCT02972840.
Thank you for your consideration. We hope to hear from you soon.